Saltar al contenido
Merck

HPLC Analysis of Piroxicam and 2-Aminopyridine in Urine on Discovery® HS F5 after SPE using Discovery® DSC-MCAX

HPLC Analysis of Piroxicam and 2-Aminopyridine in Urine on Discovery® HS F5 after SPE using Discovery® DSC-MCAX application for SPE, application for HPLC

Materiales

analytical column

Referencia del producto
Descripción
Precios

Columna para HPLC Discovery® HS F5

5 μm particle size, L × I.D. 15 cm × 4.6 mm

SPE tube or plate

Referencia del producto
Descripción
Precios

Tubo de SPE Discovery® DSC-MCAX

bed wt. 100 mg, volume 3 mL, pk of 54

CONDITIONS

sample preparation

SPE (Solid Phase Extraction)

sample/matrix

human urine spiked with piroxicam (4 μg/mL) and 2-aminopyridine (10 μg/mL)

SPE tube/cartridge

Discovery DSC-MCAX, 100 mg/3 mL (52783-U)

condition

1 mL methanol; 1 mL 10 mM potassium phosphate, pH 3

sample addition

1 mL

washing

1 mL 10 mM potassium phosphate, pH 3; 1 mL methanol

elution

1 mL 5% ammonium hydroxide in methanol

eluate post-treatment

evaporate to dryness with nitrogen at room temperature, reconstitute in 1 mL mobile phase

column

Discovery HS F5, 15 cm x 4.6 mm I.D., 5 μm particles (567516-U)

mobile phase

[A] 10 mM potassium phosphate, pH 6: [B] acetonitrile (85:15, A:B)

flow rate

2 mL/min

column temp.

25 °C

detector

UV, 220 nm

injection

10 μL

Descripción

Application

Sample Pre-Treatment:
Piroxicam and 2-aminopyridine (piroxicam′s polar metabolite) was spiked into human urine at the levels of 4 and 10 μg/mL, respectively. The urine sample was diluted 1:1 with 10 mM potassium phosphate, pH 3.

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany